Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Infigratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 known ✓ | P22607 | 13/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 11/20 | 1.00 |
| ▸ | FGFR4 known ✓ | P22455 | 7/20 | 1.00 |
| ▸ | FGFR2 known ✓ | P21802 | 5/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Infigratinib SCHEMBL374435 | 0.97 | FGFR3 (1.00) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL16383021 | 0.93 | FGFR3 (0.92) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL12596389 | 0.92 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL2013451 | 0.92 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL2011033 | 0.92 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL23281490 | 0.92 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL19338005 | 0.92 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL22532488 | 0.89 | FGFR3 (0.85) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL18398033 | 0.89 | FGFR3 (0.85) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL2014363 | 0.89 | FGFR1 (0.84) | FGFR3FGFR1FGFR4FGFR2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4676486-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | QED THERAPEUTICS, INC. (US) | 2025-07-15 | — | — | US | claimed |
| WO-2025090870-A1 | INFIGRATINIB AND METABOLITES THEREOF FOR USE IN METHODS OF TREATING SKELETAL DISORDERS | QED THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-20240398798-A1 | FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS | NOVARTIS AG (CH) | 2024-12-05 | — | — | US | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| WO-2024186882-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | claimed |
| CN-109718239-B | FGFR inhibitors for treatment of hypophosphatemic diseases | 诺华股份有限公司 | 2024-09-10 | — | — | CN | claimed |
| US-20240009193-A1 | METHODS OF TREATING ACHONDROPLASIA | CALCILYTIX THERAPEUTICS INC. | 2024-01-11 | — | — | US | claimed |
| WO-2023230233-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2023-11-30 | — | — | WO | claimed |
| WO-2023220192-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | FOUNDATION MEDICINE, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| WO-2023212572-A2 | LONG NON-CODING RNA 122 (LNC122) FOR TREATING CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-02 | — | — | WO | claimed |
| EP-4262774-A1 | METHODS OF TREATING ACHONDROPLASIA | QED Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| US-20230151434-A1 | REAWAKENING OF DORMANT TUMOR CELLS BY MODIFIED LIPIDS DERIVED FROM STRESS ACTIVATED NEUTROPHILS | WISTAR INST (US) | 2023-05-18 | — | — | US | claimed |
| WO-2022133212-A1 | METHODS OF TREATING ACHONDROPLASIA | QED THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20170304313-A1 | Therapeutic Combination For The Treatment Of Cancer | NOVARTIS AG (CH) | 2017-10-26 | — | — | US | claimed |
| WO-2016055916-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2016-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009193-A1 | METHODS OF TREATING ACHONDROPLASIA | FGFR3, FGF2, FGF1 | FGFR3 1/4885FGFR1 4/4885FGFR4 36/4885 |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | KRAS, SLC10A2, SLC10A1 | FGFR3 12/4885FGFR1 18/4885FGFR4 25/4885 |
| US-20240398798-A1 | FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS | FGFR3, FGFR1, FGFR2 | FGFR3 1/4885FGFR1 2/4885FGFR4 4/4885 |
| US-20170304313-A1 | Therapeutic Combination For The Treatment Of Cancer | FGFR3, EGFR, FGFR2 | FGFR3 1/4885FGFR1 7/4885FGFR4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.